Header Forschung

Translational Medical Oncology, Prof. Dr. Hanno Glimm

The Department for Translational Medical Oncology investigates the molecular and cellular mechanisms for cancer development, proliferation and evolution. The department engages in clinical as well as experimental activities to ensure a rapid turnaround of scientific results into clinical application and clinical outcome into new hypotheses. Experimentally, high-throughput, multi-parametric molecular profiling is used to discover differences in the genome of tumor and normal cells to identify novel targets for cancer therapy on the genomic or cellular level.

The group develops suitable model systems to functionally and mechanistically characterize their impact and assess the potential for clinical application. Clinically, a dedicated personalized oncology outpatient clinic provides consulting appointments to initiate innovative diagnostic approaches, and organizes a tumor board to discuss results of genetic tumor profiling and molecularly guided treatment strategies.

Understanding and targeting alterations in cancer

Unique alterations within tumor cells can be targets for novel treatment approaches. Scientists of the department for Translational Medical Oncology are working on identifying pivotal gene alterations and cellular subtypes that are responsible for initiating or fueling tumor growth and metastasis formation. Within individual patient tumors, a small fraction of all cells drives long-term tumor growth and metastases. Targeting this tumor-initiating cells (TIC) activity is essential to improve the long-term outcome in advanced solid cancers. The lab has developed and extensively characterized a bank of primary in vitro and in vivo models derived from solid patient tumors, e.g. CRC, PDAC and sarcomas. These functionally and genetically heterogeneous models are utilized to identify therapy relevant alterations and synthetic lethal interactions, e.g. by large scale shRNA knockdown or overexpression screening approaches. Following functional testing of potential therapeutic target alterations, targeted therapeutic strategies are developed and translated into the clinic.

The Glimm Lab, represented by the Department of Translational Medical Oncology in Dresden and the Translational Functional Cancer Genomics group in Heidelberg, welcomes researchers at both NCT partner sites to join their expertise in collaborating on these research questions.

Dr. Claudia Ball
Senior Scientist, Head of Laboratory
Email: claudia.ball(at)nct-dresden.de

NCT MASTER Registry trial for patients

In an interdisciplinary approach, new discoveries are directly transferred into treatment recommendations using the NCT/DKTK MASTER registry trial. The NCT-MASTER (Molecularly Aided Stratification for Tumor Eradication) protocol consents young patients or patients with rare tumor diseases for molecular diagnostics approaches with the explicit purpose of evaluating and stratifying for the best molecular treatment strategy and enrolment in diagnostic and therapeutic trials. The NCT MASTER is a joint NCT program between NCT Heidelberg and NCT/UCC Dresden. You can find more information about registering for the program here or download the flyer here.

Center for Personalized Oncology

The NCT/UCC Dresden Center for Personalized Oncology aims at translating latest research as well as innovative technologies and cancer therapies into clinical practice. A dedicated personalized oncology outpatient clinic provides consulting appointments to discuss innovative diagnostic approaches, results of genetic tumor profiling and molecularly guided treatment strategies. Clinical data and results of molecular analyses as well as potential therapeutic implications are discussed within a personalized oncology tumorboard participated by an interdisciplinary team of specialists in molecular diagnostics, targeted cancer therapy as well as involved clinical departments.

Dr. Christoph Heining
Senior Attending Physician
Email: christoph.heining(at)nct-dresden.de

Team members

 

 

 

Prof. Dr. Hanno Glimm
Head of Department
Translational Medical Oncology
Phone: +49 (0)351 458 5531
E-Mail: hanno.glimm(at)nct-dresden.de

Juliana Hellmold
Secretary
Phone: +49 (0)351 458 5531
E-Mail: juliana.hellmold(at)nct-dresden.de

Dr. Daniela Richter
Scientific and Administrative Coordinator
Phone: +49 (0)351 458 5539
E-Mail: daniela.richter(at)nct-dresden.de

It is important to know that cytostatics can also have side effects on the cell division processes of healthy cells, for example, in the skin, mucosa, hair, and hematopoietic cells of the bone marrow. However, most of the side effects disappear after having completed chemotherapy.

In recent years there has been an increase in combining so-called targeted drugs. These include mainly antibodies and kinase inhibitors. Depending on the type of tumor, these targeted drugs are used either individually or in combination with cytostatics. Often enough, the combination of drugs leads to a more effective treatment of the tumor disease. The use of a certain drug combination strongly depends on the type and stage of the individual patient's cancer.

Chemotherapy can be reasonable in different stages of various tumor diseases. Depending on the individual case, it can be employed either before or after surgical removal of the tumor (so-called neoadjuvant or adjuvant chemotherapy), in combination with radiation therapy, or independently from surgery or radiation therapy.

Thesis topics

The department constantly offers thesis topics for highly motivated Bsc-, Msc- or MD students. If you are interested, please send your informal application to us via email.